JP2004509857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509857A5 JP2004509857A5 JP2002515891A JP2002515891A JP2004509857A5 JP 2004509857 A5 JP2004509857 A5 JP 2004509857A5 JP 2002515891 A JP2002515891 A JP 2002515891A JP 2002515891 A JP2002515891 A JP 2002515891A JP 2004509857 A5 JP2004509857 A5 JP 2004509857A5
- Authority
- JP
- Japan
- Prior art keywords
- dimethylethyl
- oxazolyl
- thiazolyl
- thio
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 description 12
- 239000012453 solvate Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- USAKOZCUIYTREA-LLVKDONJSA-N (3r)-n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)[C@H]1CNCCC1 USAKOZCUIYTREA-LLVKDONJSA-N 0.000 description 2
- 0 C*(C)c1cnc(CSc2cnc(NC(C3CN(*)CCC3)=O)[s]2)[o]1 Chemical compound C*(C)c1cnc(CSc2cnc(NC(C3CN(*)CCC3)=O)[s]2)[o]1 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- USAKOZCUIYTREA-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CNCCC1 USAKOZCUIYTREA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- USAKOZCUIYTREA-NSHDSACASA-N (3s)-n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)[C@@H]1CNCCC1 USAKOZCUIYTREA-NSHDSACASA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- -1 dihydrochloride Chemical compound 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- LURBGHNXFQSPMM-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-(2,3-dihydroxypropyl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCN(CC(O)CO)CC1 LURBGHNXFQSPMM-UHFFFAOYSA-N 0.000 description 1
- NASKBLMGBFRGIF-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-(2-hydroxyethyl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCN(CCO)CC1 NASKBLMGBFRGIF-UHFFFAOYSA-N 0.000 description 1
- BMJRSDXYHRHHKI-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-cyclopropylpiperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCN(C2CC2)CC1 BMJRSDXYHRHHKI-UHFFFAOYSA-N 0.000 description 1
- JJJVIPYJUNRQTI-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-propan-2-ylpiperidine-4-carboxamide Chemical compound C1CN(C(C)C)CCC1C(=O)NC(S1)=NC=C1SCC1=NC=C(C(C)(C)C)O1 JJJVIPYJUNRQTI-UHFFFAOYSA-N 0.000 description 1
- IYLMWEFXWOERFM-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]cyclohexanecarboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCCCC1 IYLMWEFXWOERFM-UHFFFAOYSA-N 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 式I:
【化1】
[式中、
Rは、アルキル;
R1は、水素またはアルキル;
Xは、NR2またはCHNR2R3;
R2およびR3は各々独立して、水素、アルキル、置換アルキル、シクロアルキルまたは置換シクロアルキル;および
nは、0、1、2または3である]
で示される化合物、またはそのエナンチオマー、ジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項2】 Rが、アルキル;
R1が水素;XがNR2またはCHNR2R3;
R2およびR3が各々独立して、水素、アルキル、置換アルキルまたはシクロアルキル;および
nが2である請求項1に記載の化合物。
【請求項3】 式Ia:
【化2】
[式中、
R2は、水素、アルキル、置換アルキルまたはシクロアルキルである]
で示される請求項1に記載の化合物、またはそのエナンチオマー、ジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項4】 式Ib:
【化3】
[式中、
R2は、水素、アルキル、置換アルキルまたはシクロアルキルである]
で示される請求項1に記載の化合物、またはそのエナンチオマー、ジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項5】 式Ic:
【化4】
[式中、
R2およびR3は各々独立して、水素、アルキル、置換アルキルまたはシクロアルキルである]
で示される請求項1に記載の化合物、またはそのエナンチオマー、ジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項6】 N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−4−ピペリジンカルボキサミド;
(±)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−3−ピペリジンカルボキサミド;
(±)−1−(2,3−ジヒドロキシプロピル)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−4−ピペリジンカルボキサミド;
N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−1−(1−メチルエチル)−4−ピペリジンカルボキサミド;
1−シクロプロピル−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−4−ピペリジンカルボキサミド;
N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−1−(2−ヒドロキシエチル)−4−ピペリジンカルボキサミド;
(R)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−3−ピペリジンカルボキサミド;
(S)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル)メチル]チオ]−2−チアゾリル]−3−ピペリジンカルボキサミド;
シス−4−アミノ−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]シクロヘキシルカルボキサミド;および
トランス−4−アミノ−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]シクロヘキシルカルボキサミド
からなる群から選ばれる、請求項1に記載の化合物、またはそのエナンチオマー、ジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項7】 N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−4−ピペリジンカルボキサミド、またはその溶媒化合物もしくは医薬的に許容し得る塩。
【請求項8】 (±)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−3−ピペリジンカルボキサミド、またはそのエナンチオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項9】 (R)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−3−ピペリジンカルボキサミド、またはそのエナンチオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項10】 (S)−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]−3−ピペリジンカルボキサミド、またはそのエナンチオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項11】 シス−4−アミノ−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]シクロヘキシルカルボキサミド、またはそのジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項12】 トランス−4−アミノ−N−[5−[[[5−(1,1−ジメチルエチル)−2−オキサゾリル]メチル]チオ]−2−チアゾリル]シクロヘキシルカルボキサミド、またはそのジアステレオマー、溶媒化合物もしくは医薬的に許容し得る塩。
【請求項13】 医薬的に許容し得る塩が、塩酸塩、ニ塩酸塩、硫酸塩、トリフルオロ酢酸塩、トリフルオロ酢酸塩と塩酸塩の混合物、酒石酸塩、フマル酸塩、コハク酸塩、マレイン酸塩、クエン酸塩、メタンスルホン酸塩、臭素酸塩およびヨウ素酸塩からなる群から選ばれる、請求項1〜12のいずれか1つに記載の化合物。
【請求項14】 請求項1〜13のいずれか1つに記載の化合物および医薬的に許容し得る担体を含む、医薬組成物。
【請求項15】 請求項1〜13のいずれか1つに記載の化合物を、医薬的に許容し得る担体および抗癌剤と組合せて一定用量として製剤化したことから成る医薬組成物。
【請求項16】 請求項1〜13のいずれか1つに記載の化合物を、医薬的に許容し得る担体およびp53トランス活性化のモジュレーターと組合せて一定用量として製剤化したことからなる医薬組成物。
[Claims]
1. Formula I:
Embedded image
[Where,
R is alkyl;
R 1 is hydrogen or alkyl;
X is NR 2 or CHNR 2 R 3 ;
R 2 and R 3 are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl; and n is 0, 1, 2, or 3]
Or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
2. R is alkyl;
R 1 is hydrogen; X is NR 2 or CHNR 2 R 3 ;
The compound according to claim 1, wherein R 2 and R 3 are each independently hydrogen, alkyl, substituted alkyl or cycloalkyl; and n is 2.
3. Formula Ia:
Embedded image
[Where,
R 2 is hydrogen, alkyl, substituted alkyl or cycloalkyl.
Or a compound thereof, or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
4. Formula Ib:
Embedded image
[Where,
R 2 is hydrogen, alkyl, substituted alkyl or cycloalkyl.
Or a compound thereof, or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
5. Formula Ic:
Embedded image
[Where,
R 2 and R 3 are each independently hydrogen, alkyl, substituted alkyl or cycloalkyl.
Or a compound thereof, or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
6. N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide;
(±) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -3-piperidinecarboxamide;
(±) -1- (2,3-dihydroxypropyl) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -4- Piperidine carboxamide;
N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -1- (1-methylethyl) -4-piperidinecarboxamide;
1-cyclopropyl-N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide;
N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -1- (2-hydroxyethyl) -4-piperidinecarboxamide;
(R) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -3-piperidinecarboxamide;
(S) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl) methyl] thio] -2-thiazolyl] -3-piperidinecarboxamide;
Trans-4-amino-N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] cyclohexylcarboxamide; and trans-4-amino-N- The compound according to claim 1, which is selected from the group consisting of [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] cyclohexylcarboxamide, or an enantiomer thereof. , Diastereomers, solvates or pharmaceutically acceptable salts.
7. N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide, or a solvate or medicament thereof Acceptable salts.
8. (±) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -3-piperidinecarboxamide or an enantiomer thereof , Solvates or pharmaceutically acceptable salts.
9. (R) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -3-piperidinecarboxamide or an enantiomer thereof , Solvates or pharmaceutically acceptable salts.
10. (S) -N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -3-piperidinecarboxamide or an enantiomer thereof , Solvates or pharmaceutically acceptable salts.
11. cis-4-amino-N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] cyclohexylcarboxamide, or a diastereomer thereof , Solvates or pharmaceutically acceptable salts.
12. Trans-4-amino-N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] cyclohexylcarboxamide or a diastereomer thereof , Solvates or pharmaceutically acceptable salts.
13. A pharmaceutically acceptable salt comprising: hydrochloride, dihydrochloride, sulfate, trifluoroacetate, a mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate; The compound according to any one of claims 1 to 12, wherein the compound is selected from the group consisting of maleate, citrate, methanesulfonate, bromate and iodate.
14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 formulated as a fixed dose in combination with a pharmaceutically acceptable carrier and an anticancer agent.
16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 formulated as a fixed dose in combination with a pharmaceutically acceptable carrier and a modulator of p53 transactivation. .
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61662700A | 2000-07-26 | 2000-07-26 | |
US09/727,957 US6515004B1 (en) | 1999-12-15 | 2000-12-01 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US09/746,060 US6414156B2 (en) | 1998-10-21 | 2000-12-22 | Process for preparing azacycloalkanoylaminothiazoles |
PCT/US2001/015081 WO2002010162A1 (en) | 2000-07-26 | 2001-05-09 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004509857A JP2004509857A (en) | 2004-04-02 |
JP2004509857A5 true JP2004509857A5 (en) | 2008-06-19 |
Family
ID=27417184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002515891A Withdrawn JP2004509857A (en) | 2000-07-26 | 2001-05-09 | N- [5-[[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors of cyclin-dependent kinases |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1303513A1 (en) |
JP (1) | JP2004509857A (en) |
KR (1) | KR20030016429A (en) |
CN (1) | CN100457753C (en) |
AR (1) | AR030563A1 (en) |
AU (1) | AU2001259704A1 (en) |
BG (1) | BG65132B1 (en) |
BR (1) | BR0112674A (en) |
CA (1) | CA2417254A1 (en) |
CZ (1) | CZ2003237A3 (en) |
EE (1) | EE200300041A (en) |
EG (1) | EG24409A (en) |
GE (1) | GEP20043367B (en) |
HR (1) | HRP20030116A2 (en) |
HU (1) | HUP0303698A2 (en) |
IL (2) | IL153591A0 (en) |
LV (1) | LV13037B (en) |
MX (1) | MXPA03000774A (en) |
MY (1) | MY129635A (en) |
NO (1) | NO20030394L (en) |
PL (1) | PL365170A1 (en) |
SI (1) | SI21099A (en) |
SK (1) | SK18392002A3 (en) |
TW (1) | TWI302533B (en) |
WO (1) | WO2002010162A1 (en) |
YU (1) | YU4903A (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
EP2311818B1 (en) * | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
MY138201A (en) | 2002-09-04 | 2009-05-29 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
JP2006500391A (en) | 2002-09-04 | 2006-01-05 | シェーリング コーポレイション | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
EP1543008B1 (en) | 2002-09-23 | 2007-11-07 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
KR20060010709A (en) | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
EP1555264A1 (en) * | 2004-01-15 | 2005-07-20 | Sireen AG | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. |
DE102005008310A1 (en) * | 2005-02-17 | 2006-08-24 | Schering Ag | Use of CDKII inhibitors for fertility control |
EP1928865A1 (en) * | 2005-08-17 | 2008-06-11 | Schering Corporation | Novel high affinity thiophene-based and furan-based kinase ligands |
EP1931641B1 (en) | 2005-09-09 | 2010-08-25 | Schering Corporation | NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI |
RU2008117298A (en) | 2005-10-06 | 2009-11-20 | Шеринг Корпорейшн (US) | Pyrazolopyrimidines as Protein Kinase Inhibitors |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
EP2044066A2 (en) * | 2006-06-06 | 2009-04-08 | Bristol-Myers Squibb Company | Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide |
AU2007314342B2 (en) | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
EP2078004B1 (en) | 2006-10-31 | 2015-02-25 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
JP2010526809A (en) | 2007-05-08 | 2010-08-05 | シェーリング コーポレイション | Methods of treatment using intravenous formulations containing temozolomide |
TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
US8669259B2 (en) | 2009-08-26 | 2014-03-11 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
US20150051227A1 (en) | 2012-03-30 | 2015-02-19 | Merck Sharp & Dohme Corp. | Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor |
WO2015081867A1 (en) * | 2013-12-04 | 2015-06-11 | 杭州民生药物研究院有限公司 | Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
JP2002518380A (en) * | 1998-06-18 | 2002-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Carbon-substituted aminothiazole inhibitors of cyclin-dependent kinases |
US6414156B2 (en) * | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
MY125768A (en) * | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
-
2001
- 2001-05-09 YU YU4903A patent/YU4903A/en unknown
- 2001-05-09 AU AU2001259704A patent/AU2001259704A1/en not_active Abandoned
- 2001-05-09 JP JP2002515891A patent/JP2004509857A/en not_active Withdrawn
- 2001-05-09 IL IL15359101A patent/IL153591A0/en unknown
- 2001-05-09 BR BR0112674-1A patent/BR0112674A/en not_active Application Discontinuation
- 2001-05-09 HU HU0303698A patent/HUP0303698A2/en unknown
- 2001-05-09 GE GE5063A patent/GEP20043367B/en unknown
- 2001-05-09 WO PCT/US2001/015081 patent/WO2002010162A1/en not_active Application Discontinuation
- 2001-05-09 CN CNB018133673A patent/CN100457753C/en not_active Expired - Fee Related
- 2001-05-09 PL PL01365170A patent/PL365170A1/en not_active Application Discontinuation
- 2001-05-09 EE EEP200300041A patent/EE200300041A/en unknown
- 2001-05-09 KR KR10-2003-7001141A patent/KR20030016429A/en not_active Application Discontinuation
- 2001-05-09 SI SI200120051A patent/SI21099A/en not_active IP Right Cessation
- 2001-05-09 EP EP01933266A patent/EP1303513A1/en not_active Withdrawn
- 2001-05-09 MX MXPA03000774A patent/MXPA03000774A/en unknown
- 2001-05-09 CA CA002417254A patent/CA2417254A1/en not_active Abandoned
- 2001-05-09 CZ CZ2003237A patent/CZ2003237A3/en unknown
- 2001-05-09 SK SK1839-2002A patent/SK18392002A3/en unknown
- 2001-05-16 TW TW090111741A patent/TWI302533B/en not_active IP Right Cessation
- 2001-05-22 MY MYPI20012414A patent/MY129635A/en unknown
- 2001-05-23 EG EG20010550A patent/EG24409A/en active
- 2001-05-24 AR ARP010102516A patent/AR030563A1/en unknown
-
2002
- 2002-12-23 IL IL153591A patent/IL153591A/en not_active IP Right Cessation
-
2003
- 2003-01-16 BG BG107468A patent/BG65132B1/en unknown
- 2003-01-24 NO NO20030394A patent/NO20030394L/en not_active Application Discontinuation
- 2003-02-19 HR HR20030116A patent/HRP20030116A2/en not_active Application Discontinuation
- 2003-02-26 LV LVP-03-24A patent/LV13037B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004509857A5 (en) | ||
AU2001293936B2 (en) | Association of the CB1 receptor antagonist and sibutramin, for treating obesity | |
US7037944B2 (en) | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | |
RU2445095C2 (en) | New pharmaceutical compositions for sexual disorders | |
JP2008521827A5 (en) | ||
RU2317294C2 (en) | (imidazol-1-ylmethyl)pyridazine as blocker of nmda receptor | |
JP2004532209A5 (en) | ||
JP2001526218A5 (en) | ||
JP2008538741A (en) | Pharmaceutical composition for the treatment and / or prevention of depression | |
JP2005526723A5 (en) | ||
JP2003506354A5 (en) | ||
CA2430065A1 (en) | Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents | |
RU2002119016A (en) | N- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors of cyclin-dependent kinases | |
JP2005513103A5 (en) | ||
JP2002514623A5 (en) | ||
JP2016027024A5 (en) | ||
JP2006523652A (en) | Paroxetine and 2- (S)-(4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (R)-(3,5-bis- for the treatment of depression and / or anxiety Combinations comprising trifluoro-2-methyl-phenyl) -ethyl] -methylamide | |
RU2006126828A (en) | NK-1 NEUROKININ RECEPTOR ANTAGONISTS FOR EXITING ANNEASIS | |
JP2005511571A5 (en) | ||
JP2009501205A (en) | Psychiatric treatment composition | |
JP2005041866A (en) | Pain threshold decline inhibitor | |
JP2005511561A5 (en) | ||
TW201536282A (en) | DIMIRACETAM in the treatment of depression | |
US20070043111A1 (en) | Use of ifenprodril in the treatment of pain |